

Without Cirrhosis

TABLE 133: SVR GENOTYPE 3 WITHOUT CIRRHOSIS TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	1.47 (1.32 to 1.59)	28.43 (19.53 to 34.98)
DCV12 + SOF12		1.54 (1.31 to 1.67)	33.24 (18.76 to 39.26)
SOF12 + PR12		1.38 (0.88 to 1.62)	23.40 (−7.29 to 37.06)
DCV12 + SOF12	SOF24 + RBV24	1.05 (0.88 to 1.18)	4.66 (−10.76 to 14.60)
SOF12 + PR12		0.94 (0.60 to 1.13)	−4.92 (−36.25 to 11.22)
SOF12 + PR12	DCV12 + SOF12	0.90 (0.57 to 1.12)	−9.18 (−40.40 to 9.56)
Random effect model	Residual deviance	9.206 vs. 10 data points	
	Deviance information criteria	59.551	
Fixed effect model	Residual deviance	9.193 vs. 10 data points	
	Deviance information criteria	59.126	

Cri = credible interval; DCV = daclatasvir; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.